GT Biopharma (NASDAQ:GTBP) Trading Up 5.1% – Here’s What Happened

GT Biopharma, Inc. (NASDAQ:GTBP)’s stock price rose 5.1% during trading on Monday . The company traded as high as $0.3156 and last traded at $0.3086. 418,806 shares traded hands during trading, a decline of 46% from the average session volume of 780,414 shares. The stock had previously closed at $0.2935.

Analyst Ratings Changes

Several research analysts recently weighed in on GTBP shares. Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a research note on Wednesday, July 8th. Wall Street Zen raised shares of GT Biopharma to a “hold” rating in a research report on Saturday, June 20th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

GT Biopharma Stock Up 5.1%

The company has a market cap of $13.68 million, a PE ratio of -0.05 and a beta of 0.90. The stock’s 50 day simple moving average is $0.42 and its two-hundred day simple moving average is $0.45.

GT Biopharma (NASDAQ:GTBP) last issued its earnings results on Friday, May 15th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.03). Analysts forecast that GT Biopharma, Inc. will post -0.34 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in GT Biopharma stock. Everhart Financial Group Inc. bought a new stake in GT Biopharma, Inc. (NASDAQ:GTBP) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 100,000 shares of the company’s stock, valued at approximately $49,000. Everhart Financial Group Inc. owned approximately 0.23% of GT Biopharma as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.15% of the company’s stock.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).